CDMOs Embrace Industry 4.0 to Satisfy Customer Demand
The digitalization of bioprocessing technology isn’t happening for its own sake, but to ensure that outsourced manufacturing tasks, however diverse, will be part of highly integrated processes. Contract development and manufacturing organizations (CDMOs) are driven to adopt new production technology because they need to cater to pharmaceutical firms that are interested in focusing on research and marketing. And today, pharmaceutical firms are, if anything, more interested in outsourcing production tasks than they ever were, given the increasing number of small- and medium-sized firms that lack manufacturing capabilities of their own. It may sound as though CDMOs are spoiled for opportunity.